ArticleScientific reports2026
Integrated in silico and in vitro assessment of Azadirachta indica leaf extract against multi-drug resistant Citrobacter koseri and Staphylococcus saprophyticus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azadirachta indica (Neem) is well-known for its therapeutic potential against bacteria, while Staphylococcus saprophyticus and Citrobacter koseri are significant public health threats due to their potential to cause skin infections. This study aims to identify phytocompounds from the methanolic extract of A. indica leaves and evaluate their efficacy to inhibit those bacteria through in vitro and computational approaches. The bacteria were isolated from boil-derived pus, and the extract's growth-inhibitory effect was examined by the disc diffusion method. Additionally, GC-MS identified phytochemicals remaining in the extract. The pharmacokinetic and ADMET properties of those phytochemicals were assessed via PKCSM and SwissADME servers. Screened phytocompounds were docked with functional proteins using AutoDock Vina and GLIDE. Following that, molecular dynamics simulation in GROMACS, post-simulation, and DFT analysis were conducted. Five of the sixteen phytocompounds with favorable pharmacokinetics and toxicity profiles were docked with Peptidoglycan D, D-transpeptidase MrdA of Citrobacter koseri, and D-alanine--D-alanine ligase of Staphylococcus saprophyticus. Among them, 2-(Acetoxymethyl)-3-(methoxycarbonyl)biphenylene, and Cyclopropane-1-carboxamide, 2-butyl-N-(5,6,7,8-tetrahydro-7,7-dimethyl-5-oxoquinazolin-2-yl)- demonstrated higher binding affinity, greater stability, and smaller energy gap in docking, simulation, and DFT analysis, respectively. This study highlights the two compounds as promising lead phytocompounds to inhibit those bacteria. Further in vivo investigations are essential to validate their therapeutic effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.